Zydus Lifesciences Ltd Share Price

Q: What is the share price of Zydus Lifesciences Ltd today?

Zydus Lifesciences Ltd share price as on 22 Jan 2025 is ₹977.4

Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg

NSE: ZYDUSLIFE Large Cap ISIN: INE010B01027

As on 22 January 2025 at 15:04 IST

₹977.40

-8.50

(-0.86%)

Sell Buy

About Zydus Lifesciences Ltd

Zydus Lifesciences Ltd., previously known as Cadila Healthcare Ltd., is a prominent Indian pharmaceutical company. Founded by Ramanbhai Patel and Indravadan Modi in the city of Ahmedabad, Gujarat, the company has a rich history dating back to 1952. Specializing in pharmaceutical research, Zydus Lifesciences has established itself as a significant player in the pharmaceutical landscape. The company offers a diverse portfolio of healthcare products. Their product range encompasses generic drugs, vaccines, diagnostics, and wellness products. Notable brands like Lipaglyn, SoviHep, and Exemptia have solidified the company's reputation in the market. Read More...

Over 1 Month

1.29%

Over 6 Months

-14.61%

Over 1 Year

35.21%

Over 3 Years

140.23%

Zydus Lifesciences Ltd Summary

Close ₹ 977.40

Open ₹ 986

High ₹ 989.25

Low ₹ 963.75

Volume 4,32,441

Net Turnover (in ₹) ₹ 38,70,92,667.55

52Wk High ₹ 1,324.30

52Wk Low ₹ 706.60

52Wk High / Low

706.60

1,324.30

Zydus Lifesciences Ltd Fundamentals

Key Financial Data

Market Cap (in ₹Cr) ₹ 99,204.61

EPS (TTM) 43.26

Book Value (BV) 177.87

Div. Yield 0.30 %

P/E (TTM) 22.82

Price/Book Value 5.54

Delivery % 41.79 %

Face Value 1

Key Ratios

PE Ratio 29.38

PB Ratio 6.43

EV to Sales 9.88

PEG Ratio 0.23

ROA 15.57

ROE 23.45

Debt-Equity 0.37

Net Profit Margin 31.81

Operating Profit Margin 47.46

Zydus Lifesciences Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	19,831.50	17,424	15,334.60	14,449.10	14,367
Total Expenses	15,008.40	14,230.10	12,609.20	11,844.80	12,508
Profit Before Tax	4,808.90	2,589.70	2,838.10	2,399.20	1,495.40
Profit After Tax	3,831.40	2,001.90	2,326.40	2,205.60	1,175.60
Operating Profit after Depreciation	4,904.30	3,323.80	2,852.40	2,763.10	2,200.80

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	13,680.30	11,591.40	12,253.40	12,132.80	12,230.50
Total Non Current Assets	17,861	15,748.20	15,700.20	15,168.70	14,971.20
Total Current Assets	11,419.80	10,008.20	12,095.20	8,716	8,715.40
TOTAL ASSETS	29,280.80	25,756.40	27,795.40	23,884.70	23,686.60
Total Shareholder's Fund	19,829.50	17,515.80	16,999.60	12,992.30	10,375.70

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	3,227.90	2,688.80	2,104.50	3,293.90	2,931.50
Net Cash used in Investing Activities	-1,492.30	1,541.60	-1,017.60	-836.70	-1,004.40
Net Cash used in Financing Activities	-1,810.40	-4,400.40	-868.30	-2,547.70	-1,528.20

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	11,903.50	9,280	8,015.60	7,869.30	7,196.80
Total Expenses	7,655.10	7,044	6,532.40	5,993.30	5,587.10
Profit Before Tax	4,239.80	2,032.20	1,163.90	1,688.50	1,557.70
Profit After Tax	3,441.50	1,529.20	857.90	1,476.20	1,353.60
Operating Profit after Depreciation	4,639.10	2,514.20	1,618.10	1,946.90	1,843.60

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	4,376.60	4,184.10	4,335.90	4,112	4,109
Total Non Current Assets	16,173.50	13,405.40	10,902.60	12,431.90	11,758.80
Total Current Assets	7,911.30	7,158.20	6,837.40	6,031.70	4,792.70
TOTAL ASSETS	24,084.80	20,563.60	17,740	18,463.60	16,551.50
Total Shareholder's Fund	15,716.50	13,639.40	13,240.50	12,744.50	11,260.20

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	1,999.10	1,078.20	1,272.20	2,227.20	1,180.60
Net Cash used in Investing Activities	-1,830.60	-1,959.30	586.20	-2,713.80	54.60
Net Cash used in Financing Activities	-300.80	827	-1,709.80	255.30	-966.70

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	5,237	6,207.50	5,533.80	4,505.20	4,368.80
Total Expenses	3,775.60	4,123.50	3,903.30	3,402.80	3,223.70
Profit Before Tax	1,271.20	1,899.70	1,550.20	947.30	1,006.20
Profit After Tax	898.10	1,463.60	1,229	733.50	779.80
Operating Profit after Depreciation	1,529.90	2,147.20	1,790.10	1,161.90	1,199.10

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	2,620.60	4,160.20	3,332.40	2,371.30	2,159.30
Total Expenses	1,678.40	1,787.30	1,763.20	1,672.20	1,509.90
Profit Before Tax	1,039.30	2,233.50	1,684.90	574.30	968.10
Profit After Tax	789.80	1,700.80	1,405.20	450.40	805
Operating Profit after Depreciation	1,268.90	2,479.50	1,930.30	805.90	1,183.90

Zydus Lifesciences Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 977.45

S2 969

S3 954.75

Pivot 991.70

R1 1,000.15

R2 1,014.40

R3 1,022.85

Moving Average

20 SMA 982.34

50 SMA 973.84

100 SMA 1,015.22

200 SMA 1,051.84

Zydus Lifesciences Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

Zydus Lifesciences Ltd

₹3/Share

Announcement Date 26 Jul 2024

Record Date 26 Jul 2024

Div Yield 300%

Zydus Lifesciences Ltd Peer Comparison

Company	Price	Market Cap (in ₹ Cr)
Zydus Lifesciences Ltd	₹985.75	₹99,189.52
Sun Pharmaceuticals Industries Ltd	₹1,761.80	₹4,22,714.84
Divis Laboratories Ltd	₹5,818.40	₹1,54,460.24
Cipla Ltd	₹1,427.30	₹1,15,270.75
Dr Reddys Laboratories Ltd	₹1,288.45	₹1,07,511.36
Torrent Pharmaceuticals Ltd	₹3,157.60	₹1,06,862.73

Zydus Lifesciences Ltd News

Zydus Lifesciences to table results

On 5 February 2025

21 Jan 2025, 02:18 pm

USFDA accepts Sentynl's NDA for CUTX-101

A product candidate for treatment of Menkes disease

07 Jan 2025, 09:13 am

Volumes spurt at Zydus Lifesciences Ltd counter

Zydus Lifesciences Ltd notched up volume of 2.94 lakh shares by 10:46 IST on BSE, a 11.29 fold spurt over two-week average daily volume of 26011 shares

07 Jan 2025, 11:00 am

Zydus Life gains as arm gets USFDA nod for priority review of CUTX-101

Zydus Lifesciences rose 1.22% to Rs 974.75 after its wholly-owned subsidiary, Sentynl Therapeutics, and Fortress Biotech received U.S. food and Drug Administration approval for filing and priority review of new drug application (NDA) for CUTX-101.

07 Jan 2025, 10:02 am

Zydus Lifesciences appoints senior management personnel

03 Jan 2025, 12:56 pm

Zydus Lifesciences Ltd Stock Analysis

Annual revenue for Zydus Lifesciences Ltd increased by 28.27% to ₹11,903.50 crore in FY 2024 from ₹9,280 crore in FY 2023.
Annual Net Profit for Zydus Lifesciences Ltd increased by 125.05% to ₹3,441.50 crore in FY 2024 from ₹1,529.20 crore in FY 2023.
Promoter Shareholding in Zydus Lifesciences Ltd remains unchanged by 0.00% in the most recent quarter, from 74.98% in September 2024 to 74.98% in December 2024.
Zydus Lifesciences Ltd delivered a 1-year return of 35.21% compared to the Nifty 50, which provided a return of 8.41% as of the last trading session.
Zydus Lifesciences Ltd share price moved down by 0.86% from its previous close of INR ₹985.90. The latest Zydus Lifesciences Ltd share price is INR ₹977.40.
Zydus Lifesciences Ltd share price today has been at a low of 963.75 and a high of 989.25. Over the past 52 weeks, the Zydus Lifesciences Ltd share price has seen a low of 706.60 and a high of 1,324.30.

About Zydus Lifesciences Ltd

Zydus Lifesciences Ltd., previously known as Cadila Healthcare Ltd., is a prominent Indian pharmaceutical company. Founded by Ramanbhai Patel and Indravadan Modi in Ahmedabad, Gujarat, the company has a rich history dating back to 1952.

Specializing in pharmaceutical research, Zydus Lifesciences has established itself as a significant player in the pharmaceutical landscape. The company offers a diverse portfolio of healthcare products. Their product range encompasses generic drugs, vaccines, diagnostics, and wellness products. Notable brands like Lipaglyn, SoviHep, and Exemptia have solidified the company's reputation in the market.

The Patel family plays a pivotal role in the company's governance and strategic direction. Pankaj R. Patel holds the position of Chairman, while Sharvil P. Patel serves as the Managing Director of the company. The Patel family's major shareholding provides a strong foundation of stability, enabling the company to pursue ambitious goals and maintain robust operational strategies.

Zydus Lifesciences is one of the top pharmaceutical companies in India. However, it is not the biggest player globally. The company is managed by a team of managerial promoters who oversee its daily operations. They are –

Ganesh N Nayak
Bhadresh K Shah
Mukesh M Patel

With an experienced management team and a comprehensive approach to healthcare, Zydus Lifesciences continues to contribute significantly to the pharmaceutical sector.

The company's registered office is situated in Sur, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, Ahmedabad, Gujarat. This strategic location reflects its national presence and corporate infrastructure. Meanwhile, the registrars are based at Amaranth Business Complex, Nr. St. Xaviers Corne.

Zydus Lifesciences' commitment to innovation and strong family leadership position it as a dynamic pharmaceutical enterprise that is continuously adapting to the evolving healthcare landscape.

The Zydus Lifesciences Journey

Zydus Lifesciences Ltd. was formerly known as Cadila Healthcare. It has carved out a significant place in the global pharmaceutical industry. Established in 1952 by Ramanbhai Patel, the company is headquartered in Ahmedabad, Gujarat, India. Over the decades, Zydus Lifesciences has grown from a small regional player to a leading pharmaceutical company known for its focus on innovation, quality, and patient-centric solutions.

The journey of Zydus Lifesciences began with a vision to make healthcare affordable and accessible to all. Ramanbhai Patel laid the foundation of the company with a commitment to providing high-quality medicines. In its early years, Zydus focused on developing essential medicines for the Indian market. The company's dedication to quality earned it a reputation as a reliable healthcare provider.

In the following decades, Zydus Lifesciences expanded its product portfolio and market reach. The company began developing a wide range of pharmaceutical products, including generic drugs, over-the-counter (OTC) medicines, and speciality therapeutics.

This diversification allowed Zydus to cater to various medical needs, from chronic diseases to everyday health concerns. The company's flagship products, such as Lipaglyn for diabetic dyslipidemia and Exemptia for rheumatoid arthritis, showcased its innovative capabilities.

Research and innovation have always been at the core of Zydus Lifesciences' strategy. The company has invested heavily in research and development (R&D) to develop new and improved treatments. Zydus operates multiple R&D centres where scientists work on cutting-edge technologies and novel drug delivery systems. This focus on innovation has resulted in several breakthrough products. It has also positioned Zydus as a leader in the pharmaceutical industry.

Quality is a hallmark of Zydus Lifesciences. The company adheres to stringent quality control measures at every stage of the manufacturing process. Zydus' commitment to quality is reflected in its manufacturing facilities. These facilities have the latest technology and comply with global regulatory standards. By maintaining high-quality standards, Zydus ensures that its products are safe, effective, and reliable.

The growth and success of Zydus Lifesciences can be attributed to the strong support from its promoters, the Patel family. The company's management, led by Sharvil P. Patel, has been instrumental in driving its strategic vision and growth. The Patel family's commitment to excellence and innovation has been a key factor in Zydus' journey. Their leadership has guided the company through various challenges and opportunities, ensuring sustained growth and success.

Zydus Lifesciences is recognized as one of the top pharmaceutical companies in India. The company's strong market position is a result of its comprehensive product portfolio and commitment to quality. Zydus' products are widely used and trusted by healthcare professionals and patients alike. While the company is a major player in the pharmaceutical industry, it continues to strive for greater heights, driven by its mission to improve healthcare outcomes.

Looking ahead, Zydus Lifesciences aims to further strengthen its position as a global leader in the pharmaceutical industry. The company plans to expand its product portfolio, explore new therapeutic areas, and enhance its R&D capabilities. Zydus is committed to leveraging advanced technologies to address unmet medical needs. The company's future vision is centred on improving patient outcomes and contributing to global healthcare advancements.

Overall, the journey of Zydus Lifesciences Ltd. is a testament to its unwavering commitment to quality, innovation, and patient-centric solutions.